Mercado del síndrome de Down en Asia-Pacífico: tendencias de la industria y pronóstico hasta 2028

Solicitud de índiceSolicitud de índice Hable con el analistaHable con el analista Comprar ahoraComprar ahora Consultar antes de comprarConsultar antes Informe de muestra gratuitoInforme de muestra gratuito

Mercado del síndrome de Down en Asia-Pacífico: tendencias de la industria y pronóstico hasta 2028

  • Pharmaceutical
  • Published Report
  • Mar 2021
  • Asia-Pacific
  • 350 Páginas
  • Número de tablas: 16
  • Número de figuras: 186

>Mercado de síndrome de Down en Asia-Pacífico, por tipo de enfermedad (trisomía 21, síndrome de Down por translocación y síndrome de Down en mosaico), tratamiento (diagnóstico y terapia), usuario final (hospital, clínicas, centros de atención domiciliaria, centros de terapia y otros), canal de distribución (licitación directa, ventas minoristas y otros), país (China, Japón, India, Australia, Corea del Sur, Singapur, Tailandia, Malasia, Indonesia, Filipinas, Vietnam y resto de Asia-Pacífico), tendencias de la industria y pronóstico hasta 2028

Mercado del síndrome de Down en Asia y el PacíficoAnálisis y perspectivas del mercado: mercado del síndrome de Down en Asia y el Pacífico

Se espera que el mercado del síndrome de Down gane crecimiento de mercado en el período de pronóstico de 2021 a 2028. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 16,2% en el período de pronóstico de 2021 a 2028 y se espera que alcance los USD 559,87 millones para 2028.

La creciente prevalencia del síndrome de Down y otros trastornos relacionados y la presencia de terapias en desarrollo son los principales impulsores que impulsaron la demanda del mercado en el período de pronóstico.

El síndrome de Down incluye características tales como la creciente necesidad de un producto seguro y eficaz que repercutirá en el lanzamiento de nuevos productos por parte de los fabricantes al mercado, lo que aumentará su demanda, y el aumento de la inversión en investigación y desarrollo conducirá al crecimiento del mercado.

Actualmente se están llevando a cabo diversos estudios de investigación que se espera que creen una ventaja competitiva para que los fabricantes desarrollen productos nuevos e innovadores para el síndrome de Down, lo que se espera que brinde otras oportunidades en el mercado del síndrome de Down. Sin embargo, se espera que la falta de profesionales capacitados y los efectos secundarios asociados con las terapias de tratamiento del síndrome de Down limiten el crecimiento del mercado en el período de pronóstico.

El informe de mercado sobre el síndrome de Down proporciona detalles sobre la participación de mercado, los nuevos desarrollos y el análisis de la cartera de productos, el impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsas de ingresos emergentes, cambios en las regulaciones del mercado , aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado, comuníquese con nosotros para obtener un informe de analista; nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado.

Mercado del síndrome de Down en Asia y el PacíficoAlcance y tamaño del mercado mundial del síndrome de Down

El mercado del síndrome de Down se clasifica en cuatro segmentos notables que se basan en el tipo de enfermedad, el tratamiento, el usuario final y el canal de distribución. El crecimiento entre segmentos le ayuda a analizar nichos de crecimiento y estrategias para abordar el mercado y determinar sus áreas de aplicación principales y la diferencia en sus mercados objetivo.

  • Según el tipo de enfermedad, el mercado del síndrome de Down se segmenta en trisomía 21, síndrome de Down por translocación y síndrome de Down en mosaico. En 2021, la trisomía 21 domina el mercado, ya que es el tipo más común de síndrome de Down entre tres tipos y representa aproximadamente el 95 % de todos los casos.   
  • En función del tratamiento, el mercado del síndrome de Down se segmenta en diagnóstico y terapia . En 2021, el segmento de diagnóstico domina el mercado, ya que a la mayoría de las mujeres embarazadas se les recomiendan diferentes tipos de diagnóstico, incluidas pruebas prenatales, ecografías, entre otras, para confirmar la salud del feto en desarrollo.
  • En función del usuario final, el mercado del síndrome de Down se segmenta en hospitales , clínicas, centros de atención domiciliaria, centros de terapia y otros. En 2021, el segmento hospitalario domina el mercado porque los hospitales están equipados con herramientas de diagnóstico avanzadas que permiten a las mujeres lograr resultados de diagnóstico adecuados. Además, la presencia de profesionales capacitados también mejora la precisión de los resultados.  
  • En función del canal de distribución, el mercado del síndrome de Down se segmenta en licitación directa, ventas minoristas y otros. En 2021, las licitaciones directas dominan el mercado, ya que son la principal fuente de adquisición de dispositivos y la mayoría de los centros de atención médica dependen en gran medida de las licitaciones directas para la adquisición de productos.

Análisis del mercado de síndrome de Down a nivel de país

Se analiza el mercado del síndrome de Down y se proporciona información sobre el tamaño del mercado en función del tipo de enfermedad, el tratamiento, el usuario final y el canal de distribución.

Los países cubiertos en el informe del mercado del síndrome de Down son China, Japón, India, Australia, Corea del Sur, Singapur, Tailandia, Malasia, Indonesia, Filipinas, Vietnam y el resto de Asia-Pacífico.

Se espera que la región Asia-Pacífico crezca con la tasa de crecimiento anual compuesta (CAGR) en los períodos previstos, ya que en los países de la región la conciencia sobre el síndrome de Down está aumentando muy rápidamente con la urbanización y la disponibilidad de instalaciones médicas. Se espera que China domine el mercado en la región Asia-Pacífico debido al rápido desarrollo de la infraestructura de atención médica.

La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como nuevas ventas, ventas de reemplazo, demografía del país, leyes regulatorias y aranceles de importación y exportación son algunos de los principales indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas globales y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los canales de venta se consideran al proporcionar un análisis de pronóstico de los datos del país.

La creciente conciencia sobre la enfermedad y la creciente demanda de terapias efectivas están impulsando el crecimiento del mercado del síndrome de Down

El mercado del síndrome de Down también le proporciona un análisis detallado del mercado para cada país, el crecimiento de la industria del síndrome de Down con las ventas de medicamentos para el síndrome de Down, el impacto del avance en la tecnología del síndrome de Down y los cambios en los escenarios regulatorios con su apoyo al mercado del síndrome de Down. Los datos están disponibles para el período histórico de 2011 a 2019.

Análisis del panorama competitivo y de la cuota de mercado del síndrome de Down

El panorama competitivo del mercado del síndrome de Down proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, los sitios e instalaciones de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, los procesos de prueba de productos, las aprobaciones de productos, las patentes, la amplitud y amplitud de los productos, el dominio de las aplicaciones y la curva de la línea de vida de la tecnología. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de la empresa relacionado con el mercado del síndrome de Down.

Las principales empresas que se dedican al síndrome de Down son Natera, Inc., Myriad Genetics, Inc., PerkinElmer Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Novus Biologicals (una subsidiaria de Bio-Techne, Kid Sense Child Development Corporation Pty Ltd, Abbott, Illumina, Inc. entre otras.

Muchos lanzamientos de productos y acuerdos también son iniciados por empresas de todo el mundo, lo que también está acelerando el mercado del síndrome de Down.

  • En diciembre de 2019, se demostró que el sistema de detección prenatal Prequel de Myriad Genetics, Inc. es superior a otros métodos de detección tradicionales sin ADN que se utilizan para identificar anomalías cromosómicas en mujeres embarazadas. El producto diseñado por la empresa utiliza un enfoque de secuenciación del genoma completo para identificar la trisomía de los cromosomas 21, 18 y 13. Esta iniciativa ayudó a la empresa a lograr un crecimiento lucrativo en el mercado del síndrome de Down.

La colaboración, el lanzamiento de productos, la expansión comercial, los premios y reconocimientos, las empresas conjuntas y otras estrategias del actor del mercado están mejorando el mercado de la empresa en el mercado del síndrome de Down, lo que también proporciona el beneficio para que la organización mejore su oferta para el síndrome de Down.


SKU-

Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo

  • Panel de análisis de datos interactivo
  • Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
  • Acceso de analista de investigación para personalización y consultas
  • Análisis de la competencia con panel interactivo
  • Últimas noticias, actualizaciones y análisis de tendencias
  • Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Solicitud de demostración

Tabla de contenido

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA-PACIFIC DOWN SYNDROME MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TREATMENT OF DOWN SYNDROME LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 ASIA-PACIFIC DOWN SYNDROME MARKET: PIPELINE ANALYSIS

4.1 PIPELINE PRODUCTS IMPACT ANALYSIS

4.2 NNI-351

4.3 ASPARAGINASE

4.4 ANVS-401

4.5 QUILLIVANT XR

4.6 TOFACITINIB

4.7 MEMANTINE HYDROCHLORIDE

4.8 NICOTINE

4.9 AEF0217

4.1 ACI-24

5 ASIA-PACIFIC DOWN SYNDROME MARKET: LAWS AND REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE OF DOWN SYNDROME

6.1.2 RISING DEMAND OF EFFECTIVE THERAPIES

6.1.3 RISING AWARENESS ABOUT THE DISEASE

6.1.4 TECHNOLOGICAL ADVANCEMENTS

6.1.5 INCREASING GOVERNMENT SUPPORT

6.2 RESTRAINTS

6.2.1 UNAVAILABILITY OF ANY SPECIFIC TREATMENT

6.2.2 SIDE EFFECTS ASSOCIATED WITH DOWN SYNDROME TREATMENT THERAPIES

6.2.3 HIGH COST OF DIAGNOSIS

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS

6.3.2 INCREASING RESEARCH AND DEVELOPMENT

6.3.3 PRESENCE OF PIPELINE THERAPIES

6.3.4 PRESENCE OF REIMBURSEMENT

6.4 CHALLENGES

6.4.1 LACK OF SKILLED PROFFESSIONALS

6.4.2 LONG PROCESS FOR PRODUCT LAUNCH

6.4.3 TRANSFER OF COVID-19 INFECTIONS BY DIAGNOSTIC METHODS

7 IMPACT OF COVID-19 ON ASIA-PACIFIC DOWN SYNDROME MARKET

7.1 PRICE IMPACT

7.2 IMPACT ON SUPPLY CHAIN

7.3 IMPACT ON DEMAND

7.4 STRATEGIC DECISIONS FOR MANUFACTURERS

7.5 CONCLUSION

8 ASIA-PACIFIC DOWN SYNDROME MARKET, BY DISEASE TYPE

8.1 OVERVIEW

8.2 TRISOMY 21

8.3 TRANSLOCATION DOWN SYNDROME

8.4 MOSAIC DOWN SYNDROME

9 ASIA-PACIFIC DOWN SYNDROME MARKET, BY TREATMENT

9.1 OVERVIEW

9.2 DIAGNOSIS

9.2.1 SCREENING TESTS

9.2.1.1 First Trimester

9.2.1.1.1 Blood Test

9.2.1.1.2 Nuchal Translucency Testing

9.2.1.2 Integrated Screening Test

9.2.1.2.1 First Trimester

9.2.1.2.2 Second Trimester

9.2.1.3 The Triple Screen or Quadraple Screen Test

9.2.1.4 Ultrasound

9.2.1.5 Cell Free DNA

9.2.2 DIAGNOSTIC TESTS

9.2.2.1 Chronic Villus Sampling

9.2.2.2 Amniocentesis

9.2.2.3 Precutaneous Umbical Cord Sampling

9.3 THERAPY

9.3.1 EARLY INTERVENTION THERAPY

9.3.1.1 Speech-Language Therapy

9.3.1.2 Physical Therapy

9.3.1.3 Occupational Therapy

9.3.1.4 Others

9.3.2 ASSISTIVE TECHNOLOGY

9.3.2.1 Hearing Aids

9.3.2.2 Glasses

9.3.2.3 Others

9.3.3 SURGERY

9.3.3.1 Atrioventricular Septal Defect (AVSD)

9.3.3.2 Duodenal Atresia

9.3.3.3 Others

9.3.4 OTHERS

10 ASIA-PACIFIC DOWN SYNDROME MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITAL

10.3 CLINICS

10.4 HOMECARE SETTING

10.5 OTHERS

11 ASIA-PACIFIC DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL

11.1 OVERVIEW

11.2 DIRECT TENDER

11.3 RETAIL SALES

11.4 OTHERS

12 ASIA-PACIFIC DOWN SYNDROME MARKET, BY GEOGRAPHY

12.1 ASIA-PACIFIC

12.1.1 CHINA

12.1.2 JAPAN

12.1.3 AUSTRALIA

12.1.4 SOUTH KOREA

12.1.5 INDIA

12.1.6 SINGAPORE

12.1.7 THAILAND

12.1.8 MALAYSIA

12.1.9 INDONESIA

12.1.10 PHILIPPINES

12.1.11 VIETNAM

12.1.12 REST OF ASIA-PACIFIC

13 ASIA-PACIFIC DOWN SYNDROME MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

14 COMPANY PROFILE

14.1 F. HOFFMANN-LA ROCHE LTD

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COMPANY ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENTS

14.2 PERKINELMER INC.

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENTS

14.3 ILLUMINA, INC.

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENTS

14.4 THERMO FISHER SCIENTIFIC INC.

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENTS

14.5 MYRIAD GENETICS, INC.

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COMPANY ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENTS

14.6 ABBOTT

14.6.1 COMPANY SNAPSHOT

14.6.2 REVENUE ANALYSIS

14.6.3 PRODUCT PORTFOLIO

14.6.4 RECENT DEVELOPMENTS

14.7 ABNOVA CORPORATION

14.7.1 COMPANY SNAPSHOT

14.7.2 PRODUCT PORTFOLIO

14.7.3 RECENT DEVELOPMENTS

14.8 ASDCLINIC.CO.UK

14.8.1 COMPANY SNAPSHOT

14.8.2 SERVICE PORTFOLIO

14.8.3 RECENT DEVELOPMENT

14.9 ATILABIOSYSTEMS

14.9.1 COMPANY SNAPSHOT

14.9.2 PRODUCT PORTFOLIO

14.9.3 RECENT DEVELOPMENT

14.1 BOSTON CHILDREN'S HOSPITAL

14.10.1 COMPANY SNAPSHOT

14.10.2 SERVICE PORTFOLIO

14.10.3 RECENT DEVELOPMENTS

14.11 BOYS TOWN NATIONAL RESEARCH HOSPITAL

14.11.1 COMPANY SNAPSHOT

14.11.2 SERVICE PORTFOLIO

14.11.3 RECENT DEVELOPMENTS

14.12 CHILDREN'S HOSPITAL COLORADO

14.12.1 COMPANY SNAPSHOT

14.12.2 SERVICE PORTFOLIO

14.12.3 RECENT DEVELOPMENTS

14.13 DEMEDITEC DIAGNOSTICS GMBH

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 RECENT DEVELOPMENT

14.14 DOWN SYNDROME CORK

14.14.1 COMPANY SNAPSHOT

14.14.2 SERVICE PORTFOLIO

14.14.3 RECENT DEVELOPMENTS

14.15 MAYO CLINIC HEALTH SYSTEM

14.15.1 COMPANY SNAPSHOT

14.15.2 SERVICE PORTFOLIO

14.15.3 RECENT DEVELOPMENTS

14.16 NATERA, INC.

14.16.1 COMPANY SNAPSHOT

14.16.2 REVENUE ANALYSIS

14.16.3 PRODUCT PORTFOLIO

14.16.4 RECENT DEVELOPMENTS

14.17 NEXT BIOSCIENCES

14.17.1 COMPANY SNAPSHOT

14.17.2 PRODUCT PORTFOLIO

14.17.3 RECENT DEVELOPMENTS

14.18 NOVUS BIOLOGICALS (A SUBSIDIARY OF BIO-TECHNE)

14.18.1 COMPANY SNAPSHOT

14.18.2 REVENUE ANALYSIS

14.18.3 PRODUCT PORTFOLIO

14.18.4 RECENT DEVELOPMENT

14.19 KID SENSE CHILD DEVELOPMENT CORPORATION PTY LTD

14.19.1 COMPANY SNAPSHOT

14.19.2 SERVICE PORTFOLIO

14.19.3 RECENT DEVELOPMENT

14.2 PHYSIO.CO.UK.

14.20.1 COMPANY SNAPSHOT

14.20.2 SERVICE PORTFOLIO

14.20.3 RECENT DEVELOPMENT

14.21 SYMBOL

14.21.1 COMPANY SNAPSHOT

14.21.2 SERVICE PORTFOLIO

14.21.3 RECENT DEVELOPMENT

15 QUESTIONNAIRE

16 RELATED REPORTS

Lista de Tablas

LIST OF TABLES

TABLE 1 ASIA-PACIFIC DOWN SYNDROME MARKET: PIPELINE ANALYSIS

TABLE 2 REGULATION IMPOSED BY SEVERAL REGULATORY AGENCIES IN DIFFERENT REGIONS

TABLE 3 ASIA-PACIFIC DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 4 ASIA-PACIFIC TRISOMY 21 IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 ASIA-PACIFIC TRANSLOCATION DOWN SYNDROME IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 ASIA-PACIFIC MOSAIC DOWN SYNDROME IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 ASIA-PACIFIC DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 8 ASIA-PACIFIC DIAGNOSIS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 9 ASIA-PACIFIC DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 10 ASIA-PACIFIC DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 11 ASIA-PACIFIC FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 12 ASIA-PACIFIC INTEGRATED SCREENING TEST IN DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 13 ASIA-PACIFIC DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 14 ASIA-PACIFIC THERAPY IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 ASIA-PACIFIC THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 16 ASIA-PACIFIC EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 17 ASIA-PACIFIC ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 18 ASIA-PACIFIC SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 19 ASIA-PACIFIC THERAPY IN DOWN SYNDROM MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 20 ASIA-PACIFIC HOSPITAL IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 ASIA-PACIFIC CLINICS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 22 ASIA-PACIFIC HOMECARE SETTING IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 ASIA-PACIFIC THERAPY CENTERS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 24 ASIA-PACIFIC OTHERS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 ASIA-PACIFIC DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 26 ASIA-PACIFIC DIRECT TENDER IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 ASIA-PACIFIC RETAIL SALES IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 28 ASIA-PACIFIC OTHERS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 ASIA-PACIFIC DOWN SYNDROME MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 30 ASIA-PACIFIC DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 31 ASIA-PACIFIC DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 32 ASIA-PACIFIC DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 33 ASIA-PACIFIC SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 34 ASIA-PACIFIC FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 35 ASIA-PACIFIC INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 36 ASIA-PACIFIC DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 37 ASIA-PACIFIC THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 38 ASIA-PACIFIC EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 39 ASIA-PACIFIC ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 40 ASIA-PACIFIC SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 41 ASIA-PACIFIC DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 42 ASIA-PACIFIC DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 43 CHINA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 44 CHINA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 45 CHINA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 46 CHINA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 47 CHINA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 48 CHINA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 49 CHINA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 50 CHINA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 51 CHINA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 52 CHINA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 53 CHINA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 54 CHINA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 55 CHINA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 56 JAPAN DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 57 JAPAN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 58 JAPAN DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 59 JAPAN SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 60 JAPAN FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 61 JAPAN INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 62 JAPAN DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 63 JAPAN THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 64 JAPAN EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 65 JAPAN ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 66 JAPAN SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 67 JAPAN DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 68 JAPAN DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 69 AUSTRALIA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 70 AUSTRALIA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 71 AUSTRALIA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 72 AUSTRALIA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 73 AUSTRALIA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 74 AUSTRALIA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 75 AUSTRALIA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 76 AUSTRALIA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 77 AUSTRALIA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 78 AUSTRALIA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 79 AUSTRALIA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 80 AUSTRALIA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 81 AUSTRALIA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 82 SOUTH KOREA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 83 SOUTH KOREA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 84 SOUTH KOREA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 85 SOUTH KOREA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 86 SOUTH KOREA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 87 SOUTH KOREA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 88 SOUTH KOREA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 89 SOUTH KOREA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 90 SOUTH KOREA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 91 SOUTH KOREA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 92 SOUTH KOREA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 93 SOUTH KOREA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 94 SOUTH KOREA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 95 INDIA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 96 INDIA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 97 INDIA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 98 INDIA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 99 INDIA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 100 INDIA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 101 INDIA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 102 INDIA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 103 INDIA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 104 INDIA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 105 INDIA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 106 INDIA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 107 INDIA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 108 SINGAPORE DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 109 SINGAPORE DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 110 SINGAPORE DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 111 SINGAPORE SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 112 SINGAPORE FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 113 SINGAPORE INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 114 SINGAPORE DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 115 SINGAPORE THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 116 SINGAPORE EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 117 SINGAPORE ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 118 SINGAPORE SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 119 SINGAPORE DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 120 SINGAPORE DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 121 THAILAND DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 122 THAILAND DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 123 THAILAND DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 124 THAILAND SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 125 THAILAND FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 126 THAILAND INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 127 THAILAND DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 128 THAILAND THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 129 THAILAND EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 130 THAILAND ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 131 THAILAND SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 132 THAILAND DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 133 THAILAND DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 134 MALAYSIA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 135 MALAYSIA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 136 MALAYSIA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 137 MALAYSIA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 138 MALAYSIA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 139 MALAYSIA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 140 MALAYSIA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 141 MALAYSIA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 142 MALAYSIA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 143 MALAYSIA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 144 MALAYSIA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 145 MALAYSIA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 146 MALAYSIA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 147 INDONESIA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 148 INDONESIA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 149 INDONESIA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 150 INDONESIA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 151 INDONESIA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 152 INDONESIA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 153 INDONESIA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 154 INDONESIA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 155 INDONESIA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 156 INDONESIA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 157 INDONESIA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 158 INDONESIA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 159 INDONESIA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 160 PHILIPPINES DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 161 PHILIPPINES DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 162 PHILIPPINES DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 163 PHILIPPINES SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 164 PHILIPPINES FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 165 PHILIPPINES INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 166 PHILIPPINES DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 167 PHILIPPINES THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 168 PHILIPPINES EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 169 PHILIPPINES ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 170 PHILIPPINES SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 171 PHILIPPINES DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 172 PHILIPPINES DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 173 VIETNAM DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 174 VIETNAM DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 175 VIETNAM DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 176 VIETNAM SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 177 VIETNAM FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 178 VIETNAM INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 179 VIETNAM DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 180 VIETNAM THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 181 VIETNAM EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 182 VIETNAM ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 183 VIETNAM SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 184 VIETNAM DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 185 VIETNAM DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 186 REST OF ASIA-PACIFIC DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

 

Lista de figuras

LIST OF FIGURES

FIGURE 1 ASIA-PACIFIC DOWN SYNDROME MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC DOWN SYNDROME MARKET : DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC DOWN SYNDROME MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC DOWN SYNDROME MARKET: ASIA-PACIFIC VS. REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA-PACIFIC DOWN SYNDROME MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC DOWN SYNDROME MARKET: MULTIVARIATE MODELLING

FIGURE 7 ASIA-PACIFIC DOWN SYNDROME MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 ASIA-PACIFIC DOWN SYNDROME MARKET: DBMR MARKET POSITION GRID

FIGURE 9 ASIA-PACIFIC DOWN SYNDROME MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 ASIA-PACIFIC DOWN SYNDROME MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 ASIA-PACIFIC DOWN SYNDROME MARKET: SEGMENTATION

FIGURE 12 INCREASING PREVALENCE OF DOWN SYNDROME AND OTHER RELATED DISORDERS AND RISING DEMAND FOR EFFECTIVE THERAPIES IS DRIVING THE ASIA-PACIFIC DOWN SYNDROME MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 TRISOMY 21 SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC DOWN SYNDROME MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC DOWN SYNDROME MARKET

FIGURE 15 ASIA-PACIFIC DOWN SYNDROME MARKET: BY DISEASE TYPE, 2020

FIGURE 16 ASIA-PACIFIC DOWN SYNDROME MARKET: BY DISEASE TYPE, 2020-2028 (USD MILLION)

FIGURE 17 ASIA-PACIFIC DOWN SYNDROME MARKET: BY DISEASE TYPE, CAGR (2020-2028)

FIGURE 18 ASIA-PACIFIC DOWN SYNDROME MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 1 ASIA-PACIFIC DOWN SYNDROME MARKET: BY TREATMENT, 2020

FIGURE 2 ASIA-PACIFIC DOWN SYNDROME MARKET: BY TREATMENT, 2020-2028 (USD MILLION).

FIGURE 3 ASIA-PACIFIC DOWN SYNDROME MARKET: BY TREATMENT, CAGR (2020-2028)

FIGURE 4 ASIA-PACIFIC DOWN SYNDROME MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 5 ASIA-PACIFIC DOWN SYNDROME MARKET: BY END USER, 2020

FIGURE 6 ASIA-PACIFIC DOWN SYNDROME MARKET: BY END USER, 2020-2028 (USD MILLION)

FIGURE 7 ASIA-PACIFIC DOWN SYNDROME MARKET: BY END USER, CAGR (2020-2028)

FIGURE 8 ASIA-PACIFIC DOWN SYNDROME MARKET: BY END USER, LIFELINE CURVE

FIGURE 9 ASIA-PACIFIC DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 10 ASIA-PACIFIC DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 11 ASIA-PACIFIC DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)

FIGURE 12 ASIA-PACIFIC DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 13 ASIA-PACIFIC DOWN SYNDROME MARKET: SNAPSHOT (2020)

FIGURE 14 ASIA-PACIFIC DOWN SYNDROME MARKET: BY COUNTRY (2020)

FIGURE 15 ASIA-PACIFIC DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 16 ASIA-PACIFIC DOWN SYNDROME MARKET: BY COUNTRY (2021 - 2028)

FIGURE 17 ASIA-PACIFIC DOWN SYNDROME MARKET: BY TREATMENT (2021 & 2028)

FIGURE 18 ASIA-PACIFIC DOWN SYNDROME MARKET: COMPANY SHARE 2020 (%)

 

Ver información detallada Right Arrow

Metodología de investigación

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.

La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.

Personalización disponible

Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados ​​en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.